Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: Implications for multiple sclerosis pathogenesis and treatment

Multiple Sclerosis

Volumn 10, Issue 3, 2004, Pages 290-297

  Liuzzi, Grazia Maria ^a   Latronico, Tiziana ^a   Fasano, Anna ^a   Carlone, Giulia ^a   Riccio, Paolo ^b  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF BASILICATA   (Italy)

Author keywords

Astrocytes; Blood brain barrier; Demyelination; IFN ; Microglia; MMPs; Multiple sclerosis

Indexed keywords

BETA INTERFERON; GELATINASE A; GELATINASE B; LIPOPOLYSACCHARIDE; MATRIX METALLOPROTEINASE;

ANIMAL CELL; ARTICLE; ASTROCYTE; BRAIN INJURY; CELL ACTIVATION; CELL CULTURE; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; ENZYME INHIBITION; ENZYME RELEASE; EXPERIMENTATION; GLIA CELL; IMMUNOMODULATION; MICROGLIA; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN EXPRESSION; RAT; SUPERNATANT; ZYMOGRAPHY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ASTROCYTES; CELLS, CULTURED; CULTURE MEDIA; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INTERFERON-BETA; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICROGLIA; MULTIPLE SCLEROSIS; RATS; RNA, MESSENGER;

EID: 3042694846     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1016oa     Document Type: Article

References (42)

1. Raine CS, Cannella B, Duijvestijn AM, Cross AH. Homing to central nervous system vasculature by antigen-specific lymphocytes. II. Lymphocyte/endothelial cell adhesion during the initial stages of autoimmune demyelination. Lab Invest 1990; 63: 476-89.
2. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991; 28: 254-60.
3. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodelling. FASEB J 1991; 5: 2145-54.
4. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002; 37: 375-536.
5. Gottschall PE, Yu X. Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J Neurochem 1995; 64: 1513-20.
6. Colton CA, Keri JE, Chen WT, Monsky WL. Protease production by cultured microglia: substrate gel analysis and immobilized matrix degradation. J Neurosci Res 1993; 35: 297-304.
7. Gottschall PE, Yu X, Bing B. Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture. J Neurosci Res 1995; 42: 335-42.
8. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules and multiple sclerosis lesions. J Neuropothol Exp Neurol 1996; 55: 300-309.
9. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G et al. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 1996; 55: 1194-204.
10. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992; 41: 29-34.
11. Paemen L, Olsson T, Soderstrom M, Van Damme J, Opdenakker G. Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur J Neurol 1994; 1: 55-63.
12. Leppert D, Ford J, Stabler G, Grygar C, Lienert C, Huber S et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998; 121: 2327-34.
13. Liuzzi GM, Trojano M, Fanelli M, Avolio C, Fasano A, Livrea P et al. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler 2002; 8: 222-28.
14. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996; 40: 846-52.
15. Stuve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Williams G et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996; 40: 853-63.
16. Trojano M, Avolio C, Liuzzi GM, Ruggieri M, Defazio G, Liguori M et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 1999; 53: 1402-408.
17. Bartholome EJ, Van Aelst I, Koyen E, Kiss R, Willems F, Goldman M et al. Human monocyte-derived dendritic cells produce bioactive gelatinase B: inhibition by IFN-beta. J Interferon Cytokine Res 2001; 21: 495-501.
18. Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Common 1993; 192: 1175-81.
19. Nakajima K, Hamanoue M, Shimojo M, Takei N, Kohsaka S. Characterization of microglia isolated from a primary culture of embryonic rat brain by a simplified method. Biomed Res 1989; 10: 411-23.
20. Gebicke-Haerter PJ, Bauer J, Schobert A, Northoff H. Lipopolysaccharide-free conditions in primary astrocyte cultures allow growth and isolation of microglial cells. J Neurosci 1989; 9: 183-94.
21. McCarthy KD, de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 1980; 85: 890-902.
22. Liuzzi GM, Santacroce MP, Peumans WJ, Van Damme EJ, Dubois B, Opdenakker G et al. Regulation of gelatinases in microglia and astrocyte cell cultures by plant lectins. Glia 1999; 27: 53-61.
23. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia 2002; 39: 279-91.
24. Opdenakker G, Van Damme J. Cytokine-regulated proteases in autoimmune diseases. Immunol Today 1994; 15: 103-107.
25. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001; 2: 502-11.
26. Fosang AJ, Hardingham TE. Isolation of the N-terminal globular protein domains from cartilage proteoglycans. Identification of G2 domain and its lack of interaction with hyaluronate and link protein. Biochem J 1989; 261: 801-809.
27. Lein M, Nowak L, Jung K, Koenig F, Lichtinghagen R, Schnorr D et al. Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. Clin Biochem 1997; 30: 491-96.
28. Vos CM, Sjulson L, Nath A, McArthur JC, Pardo CA, Rothstein J et al. Cytotoxicity by matrix metalloprotease-1 in organotypic spinal cord and dissociated neuronal cultures. Exp Neurol 2000; 163: 324-30.
29. Gearing AJ, Beckett P, Cristodoulou M, Churchill M, Clements J, Davidson AH et al. Processing of tumor necrosis factor-alpha precursor by metalloproteinases. Nature 1994; 370: 555-57.
30. Chandler S, Miller KM, Clements JM, Lury J, Corkill D, Anthony DC et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 1997; 72: 155-61.
31. Ozenci V, Rinaldi L, Teleshova N, Matusevicius D, Kivisakk P, Kouwenhoven M et al. Metalloproteinases and their tissue inhibitors in multiple sclerosis. J Autoimmun 1999; 12: 297-303.
32. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 1997; 23: 406-15.
33. Cossins JA, Clements JM, Ford J, Miller KM, Pigott R, Vos W et al. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Awn Neuropathol (Berl) 1997; 94: 590-98.
34. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 662-67.
35. Yong VW, Antel JP. Major histocompatibility complex molecules on glial cells. Semin Neurosci 1992; 4: 231-40.
36. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51: 682-89.
37. Uhm JH, Dooley NP, Stuve O, Francis GS, Duquette P, Antel JP et al. Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon beta-1b therapy. Ann Neurol 1999; 46: 319-24.
38. Waubant E, Gee L, Bacchetti P, Sloan R, Cotleur A, Rudick R et al. Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS. J Neuroimmunol 2001; 112: 139-45.
39. Ma Z, Qin H, Benveniste EN. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-γ and IFN-β : critical role of STAT-1α. J Immunol 2001; 167: 5150-59.
40. Sanceau J, Boyd DD, Seiki M, Bauvois B. Interferons inhibit tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-kappa B. J Biol Chem 2002; 277: 35766-75.
41. Cuzner ML, Opdenakker G. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J Neuroimmunol 1999; 94: 1-14.
42. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993; 46: 145-53.